{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T15:23:33Z","timestamp":1782660213765,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/s41408-018-0104-5","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T11:17:26Z","timestamp":1533035846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bendamustine, pomalidomide, and dexamethasone for relapsed and\/or refractory multiple myeloma"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7453-0045","authenticated-orcid":false,"given":"Dharshan","family":"Sivaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn D","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson H","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie L","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson J","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"104_CR1","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","volume":"122","author":"MQ Lacy","year":"2013","unstructured":"Lacy, M. Q. & McCurdy, A. R. Pomalidomide. Blood 122, 2305\u20132309 (2013).","journal-title":"Blood"},{"issue":"Suppl 1","key":"104_CR2","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.critrevonc.2013.02.001","volume":"88","author":"PG Richardson","year":"2013","unstructured":"Richardson, P. G., Mark, T. M. & Lacy, M. Q. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit. Rev. Oncol. Hematol. 88(Suppl 1), S36\u2013S44 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"104_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","volume":"172","author":"E Rychak","year":"2016","unstructured":"Rychak, E. et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br. J. Haematol. 172, 889\u2013901 (2016).","journal-title":"Br. J. Haematol."},{"key":"104_CR4","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson, B. D. & Rummel, M. J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 27, 1492\u20131501 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"104_CR5","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1053\/j.seminhematol.2011.03.004","volume":"48","author":"MJ Rummel","year":"2011","unstructured":"Rummel, M. J. & Gregory, S. A. Bendamustine\u2019s emerging role in the management of lymphoid malignancies. Semin. Hematol. 48(Suppl 1), S24\u2013S36 (2011).","journal-title":"Semin. Hematol."},{"issue":"Suppl 1","key":"104_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminhematol.2011.03.001","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni, L. M. The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action--introduction. Semin. Hematol. 48(Suppl 1), S1\u2013S3 (2011).","journal-title":"Semin. Hematol."},{"key":"104_CR7","first-page":"1287","volume":"90","author":"S Knop","year":"2005","unstructured":"Knop, S. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90, 1287\u20131288 (2005).","journal-title":"Haematologica"},{"key":"104_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2141.2011.08754.x","volume":"155","author":"K Ramasamy","year":"2011","unstructured":"Ramasamy, K., Hazel, B., Mahmood, S., Corderoy, S. & Schey, S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br. J. Haematol. 155, 632\u2013634 (2011).","journal-title":"Br. J. Haematol."},{"key":"104_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.12361","volume":"162","author":"W P\u00f6nisch","year":"2013","unstructured":"P\u00f6nisch, W. et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br. J. Haematol. 162, 202\u2013209 (2013).","journal-title":"Br. J. Haematol."},{"key":"104_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berensen","year":"2013","unstructured":"Berensen, J. R. et al. Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 160, 321\u2013330 (2013).","journal-title":"Br. J. Haematol."},{"key":"104_CR11","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V128.22.3334.3334","volume":"128","author":"M Gramatzki","year":"2016","unstructured":"Gramatzki, M. et al. Carfilzomib in combination with bendamustine and dexamethasone (CBd) in relapsed and\/or refractory patients with multiple myeloma: the phase I\/II EMN09 study. Blood J 128, 3334 (2016).","journal-title":"Blood J"},{"key":"104_CR12","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","volume":"119","author":"S Lentzsch","year":"2012","unstructured":"Lentzsch, S. et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood 119, 4608\u20134613 (2012).","journal-title":"Blood"},{"key":"104_CR13","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah, J. J. et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126, 2284\u20132290 (2015).","journal-title":"Blood"},{"key":"104_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari, A. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130, 974\u2013981 (2017).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0104-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:36:18Z","timestamp":1671536178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0104-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.G. reports consultancy for, research funding from, and participation in advisory committees for Celgene, Janssen, Millennium\/Takeda, and Onyx. D.A.R. reports research funding and honoraria from Celgene. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"71"}}